MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
S. Ramesh, A. Cifci, S. Javeri, R. Minne, C. A. Longhurst, K. P. Nickel, R. Kimple, A. M. Baschnagel
This study shows that capmatinib radiosensitizes MET exon 14-mutated and MET-amplified NSCLC cells and tumors, inhibiting DNA repair and reducing tumor growth.
bioRxiv · Oct 26, 2023Cancer Biology